These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23244593)

  • 41. Effects of methoxychlor and its metabolite 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 11β-hydroxysteroid dehydrogenase activities in vitro.
    Guo J; Deng H; Li H; Zhu Q; Zhao B; Chen B; Chu Y; Ge RS
    Toxicol Lett; 2013 Mar; 218(1):18-23. PubMed ID: 23333641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolism of olaquindox in rat liver microsomes: structural elucidation of metabolites by high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry.
    Liu Z; Huang L; Dai M; Chen D; Wang Y; Tao Y; Yuan Z
    Rapid Commun Mass Spectrom; 2008 Apr; 22(7):1009-16. PubMed ID: 18320546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of high-resolution mass spectrometry to investigate a metabolite interference during liquid chromatography/tandem mass spectrometric quantification of a small molecule in toxicokinetic study samples.
    Furlong M; Bessire A; Song W; Huntington C; Groeber E
    Rapid Commun Mass Spectrom; 2010 Jul; 24(13):1902-10. PubMed ID: 20533320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
    Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Species difference in the in vitro and in vivo metabolism of amtolmetin guacil.
    Hotha KK; Dasari VB; Shaik AN; Syed M; Shivva V; Lakshmanarao RK; Korlakunta JN; Mullangi R
    Arzneimittelforschung; 2010; 60(11):667-74. PubMed ID: 21175039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).
    Véniant MM; Hale C; Hungate RW; Gahm K; Emery MG; Jona J; Joseph S; Adams J; Hague A; Moniz G; Zhang J; Bartberger MD; Li V; Syed R; Jordan S; Komorowski R; Chen MM; Cupples R; Kim KW; St Jean DJ; Johansson L; Henriksson MA; Williams M; Vallgårda J; Fotsch C; Wang M
    J Med Chem; 2010 Jun; 53(11):4481-7. PubMed ID: 20465278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LC-MS/MS bioanalytical method development for AMG 900: resolution of an isobaric interference in rodent in vivo studies.
    Be X; Moore ES; Zhao Z; Wells MC
    J Pharm Biomed Anal; 2013 Feb; 74():171-7. PubMed ID: 23245248
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism of an atypical antipsychotic agent, 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2, 5,5-trimethyl-4-thiazolidinone (HP236).
    Mutlib AE; Jurcak J; Hrib N
    Drug Metab Dispos; 1996 Oct; 24(10):1139-50. PubMed ID: 8894517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [In vivo comparison of estradiol metabolism in liver microsomes of human, Beagle dog and rat].
    Song YQ; Liao J; Liu HW; Ai CH; Zhang F
    Yao Xue Xue Bao; 2012 Feb; 47(2):210-5. PubMed ID: 22512033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
    Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
    Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
    Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
    Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
    Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD
    Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
    Kumar GN; Jayanti V; Lee RD; Whittern DN; Uchic J; Thomas S; Johnson P; Grabowski B; Sham H; Betebenner D; Kempf DJ; Denissen JF
    Drug Metab Dispos; 1999 Jan; 27(1):86-91. PubMed ID: 9884314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Rohde JJ; Pliushchev MA; Sorensen BK; Wodka D; Shuai Q; Wang J; Fung S; Monzon KM; Chiou WJ; Pan L; Deng X; Chovan LE; Ramaiya A; Mullally M; Henry RF; Stolarik DF; Imade HM; Marsh KC; Beno DW; Fey TA; Droz BA; Brune ME; Camp HS; Sham HL; Frevert EU; Jacobson PB; Link JT
    J Med Chem; 2007 Jan; 50(1):149-64. PubMed ID: 17201418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose.
    Martin IJ; Hill SE; Baker JA; Deshmukh SV; Mulrooney EF
    Drug Metab Dispos; 2016 Aug; 44(8):1435-40. PubMed ID: 27260151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liquid chromatography-mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease.
    Zhang KE; Hee B; Lee CA; Liang B; Potts BC
    Drug Metab Dispos; 2001 May; 29(5):729-34. PubMed ID: 11302940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
    Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
    Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs.
    Miao Z; Scott DO; Griffith DA; Day R; Prakash C
    Drug Metab Dispos; 2011 Dec; 39(12):2191-208. PubMed ID: 21875952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of bile acids on rat hepatic microsomal type I 11beta-hydroxysteroid dehydrogenase.
    Maeda Y; Naganuma S; Niina I; Shinohara A; Koshimoto C; Kondo K; Chijiiwa K
    Steroids; 2010 Feb; 75(2):164-8. PubMed ID: 19948178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.